Лучшие больницы для «Vulvar Cancer Treatment» в Ченнаи, Индия

Vulvar cancer is a malignancy arising from the squamous epithelium of the external female genitalia, accounting for approximately 4–5% of all gynecologic cancers globally. The vast majority—around 90%—are squamous cell carcinomas (SCC), with the remainder comprising melanomas, adenocarcinomas of Bartholin's gland, basal cell carcinomas, and rare sarcomas. Two distinct pathogenic pathways are recognized: the HPV-associated pathway, predominantly affecting younger women and linked to vulvar intraepithelial neoplasia (VIN), and the HPV-independent pathway occurring in older women with a background of lichen sclerosus or differentiated VIN. Physiologically, the disease carries significant functional and psychosexual implications, as surgical intervention may alter urinary, bowel, and sexual function, necessitating a holistic multidisciplinary approach.

• Confirmed histopathological diagnosis of vulvar malignancy (squamous cell carcinoma, melanoma, Bartholin gland adenocarcinoma, or other subtypes) via punch or incisional biopsy
• FIGO Stage I–IVA disease considered for curative-intent surgery or definitive chemoradiation
• FIGO Stage IVB or recurrent/metastatic disease considered for systemic therapy, palliative radiation, or clinical trial enrollment
• Patients with HPV-associated VIN3 or differentiated VIN with high-risk features (multifocal disease, prior treatment failure)
• Required pre-treatment diagnostics:

- MRI pelvis with contrast (to assess depth of invasion, urethral/anal proximity, and lymph node morphology)

- PET-CT scan (whole body, for nodal and distant metastasis staging in Stage IB and above)

Surgical APPROACHES:

1. Wide Local Excision (WLE) / Radical Local Excision: The standard for FIGO Stage IA (invasion ≤1 mm) involves WLE with 1 cm clinical margins. For Stage IB–II, radical local excision targets an 8 mm pathologic margin. The "three-incision" technique has replaced the classical butterfly incision for inguinofemoral lymphadenectomy, significantly reducing wound complication rates from ~50% to under 20%.

2. Sentinel Lymph Node Biopsy (SLNB): Validated by the GROINSS-V and GOG-173 trials, SLNB using a combination of technetium-99m radiocolloid and isosulfan blue or patent blue V dye—or increasingly, indocyanine green (ICG) with near-infrared (NIR) fluorescence imaging—is the standard of care for unifocal tumors <4 cm with clinically node-negative groins. Ultrastaging of sentinel nodes using serial sectioning and cytokeratin immunohistochemistry maximizes sensitivity. GROINSS-V II data support omission of full groin lymphadenectomy in patients with low-volume sentinel node metastasis (<2 mm), replacing it with concurrent chemoradiation.

3. Inguinofemoral Lymphadenectomy (IFL): Indicated when SLNB is not feasible (multifocal tumor, prior groin surgery, or failed sentinel node mapping) or when sentinel nodes are positive with macrometastasis. Superficial and deep femoral nodal dissection is performed. Sartorius muscle transposition over the femoral vessels reduces post-operative wound breakdown risk.

PRE-ARRIVAL PHASE (2–4 weeks before travel):

• GAF Healthcare coordinator contacts the patient and reviews all existing medical records, biopsy reports, imaging, and pathology
• Records are transmitted to the assigned gynecologic oncologist for virtual multidisciplinary tumor board review
• A preliminary treatment plan and cost estimate are provided within 48–72 hours
• e-Medical visa application initiated for India-bound patients (typically processed in 3–5 business days); UAE entry visa or visa-on-arrival facilitated for UAE-bound patients
• Prehabilitation guidance issued: nutritional optimization, iron supplementation if anemic, smoking cessation protocol, and pre-operative pelvic floor physiotherapy instructions

ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3):